LORVIQUA

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.

Reference
  1. Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics.

Legal Category: S1A

PP-LQA-IRL-0038 Preparation Date: September 2021